2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-106328
    Fluasterone 112859-71-9 99.84%
    Fluasterone is a potent G6PD inhibitor with a Ki of 0.51 μM. Fluasterone has anti-inflammatory, cancer preventive, and anti-diabetic effects. Fluasterone is orally active.
    Fluasterone
  • HY-112149
    ZL0420 2230496-80-5 98.0%
    ZL0420 is a potent and selective bromodomain-containing protein 4 (BRD4) inhibitor with IC50 values of 27 nM against BRD4 BD1 and 32 nM against BRD4 BD2.
    ZL0420
  • HY-112706
    PF-06747711 1892576-58-7 ≥99.0%
    PF-06747711 is a potent, selective, and orally active retinoic acid receptor-related orphan C2 (RORC2, also known as RORγt) inverse agonist, with an IC50 of 4.1 nM. Anti-skin inflammatory activity.
    PF-06747711
  • HY-114323
    PROTAC FLT-3 degrader 1 2230826-81-8 99.19%
    PROTAC FLT-3 degrader 1 is an effective and selective FLT-3 PROTAC degrader with an IC50 of 0.6 nM. PROTAC FLT-3 degrader 1 inhibits both FLT-3 and FLT-3 ITD mutants. PROTAC FLT-3 degrader 1 has the activity of anti-proliferation and induction of apoptosis, which can be used in the study of tumor.
    PROTAC FLT-3 degrader 1
  • HY-130252
    YQ128 2454246-18-3 99.74%
    YQ128 is a potent and selective second-generation NLRP3 (NOD-like receptor P3) inflammasome inhibitor with an IC50 of 0.30 μM. YQ128 significantly and selectively suppresses the production of IL-1β, but not TNF-α, and it can cross the BBB to reach the CNS. YQ128 has anti-inflammatory activity. YQ128 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    YQ128
  • HY-134820
    MLT-943 1832576-04-1 99.71%
    MLT-943 is a potent, selective and orally active MALT1 protease inhibitor. MLT-943 inhibits stimulated-IL-2 secretion in PBMC or in whole blood with a similar IC50 across species (0.07-0.09 μM in PBMC, 0.6-0.8 μM in whole blood). MLT-943 has anti-inflammatory activities and can be used for FcgR-mediated inflammation research.
    MLT-943
  • HY-135890
    CG347B 1598426-03-9 98.07%
    CG347B is a selective HDAC6 inhibitor, also involves in synthesis of other metalloenzyme inhibitors. HDAC6 inhibitors can be used for oncology, immunology, and neurology research.
    CG347B
  • HY-14305A
    BMS-582949 hydrochloride 912806-16-7 98.90%
    BMS-582949 hydrochloride is an orally active and highly selective p38α MAPK inhibitor, with an IC50 of 13 nM. BMS-582949 hydrochloride displays a significantly improved pharmacokinetic profile and is effective in inflammatory disease.
    BMS-582949 hydrochloride
  • HY-162334
    HYOU1-IN-1 2832155-52-7 98.32%
    HYOU1-IN-1 (Compound 33) is an inhibitor of hypoxia-upregulated protein 1 (HYOU1) with anti-inflammatory activity. HYOU1-IN-1 can be used in research on the regulation of fibroblast activation, chronic inflammation, and fibrotic diseases.
    HYOU1-IN-1
  • HY-163159
    NP3-562 2409825-32-5 98.16%
    NP3-562 is an orally active NLRP3 Inhibitor. NP3-562 inhibits IL-1β release in the supernatant of Nigericin (HY-127019)-stimulated THP-1 cells (IC50 = 66 nM), human whole blood (IC50 = 214 nM) and a mouse acute peritonitis model. NP3-562 can be used for the study of acute peritonitis.
    NP3-562
  • HY-129388A
    Pulrodemstat 1821307-10-1 98.86%
    Pulrodemstat (CC-90011) is a potent, selective, reversible and orally active inhibitor of lysine specific demethylase-1 (LSD1) with an IC50 of 0.25 nM. Pulrodemstat is less enzymatic inhibition against LSD2, MAO-A, and MAO-B. Pulrodemstat induces acute myeloid leukemia (AML) and small cell lung cancer (SCLC) cells differentiation and has potent anticancer activity.
    Pulrodemstat
  • HY-153701S
    Envudeucitinibum 2417135-66-9 99.56%
    Envudeucitinibum (Envudeucitinib) is a highly selective, allosteric and orally active TYK2 inhibitor binding to the JH2 domain of TYK2. Envudeucitinibum has no off-target effects on other kinases (JAK1-3). Envudeucitinibum reduces signaling and production of proinflammatory cytokines including IL-12, IL-23, IL-17, and type I interferons (IFNs). Envudeucitinibum can be used for the research of plaque psoriasis, systemic lupus erythematosus (SLE), and other immune-mediated diseases.
    Envudeucitinibum
  • HY-W003467
    Rabeprazole Sulfide 117977-21-6 99.26%
    Rabeprazole Sulfide is a sulfide metabolite of Rabeprazole (HY-B0656). Rabeprazole Sulfide inhibits Helicobacter pylori motility. Rabeprazole Sulfide can be used for the research of Helicobacter pylori infection.
    Rabeprazole Sulfide
  • HY-W018772R
    D-Ribose(mixture of isomers) (Standard) 50-69-1 98.29%
    D-Ribose(mixture of isomers) (Standard) is the analytical standard of D-Ribose(mixture of isomers). This product is intended for research and analytical applications. D-Ribose(mixture of isomers) is an energy enhancer, and acts as a sugar moiety of ATP, and widely used as a metabolic therapy supplement for chronic fatigue syndrome or cardiac energy metabolism. D-Ribose(mixture of isomers) is active in protein glycation, induces NF-κB inflammation in a RAGE-dependent manner.
    D-Ribose(mixture of isomers) (Standard)
  • HY-18324
    CRS3123 1013915-71-3 99.37%
    CRS3123 is a potent and orally active narrow-spectrum antibiotic. CRS3123 inhibits bacterial methionyl-tRNA synthetase. CRS3123 has potent activity against Clostridium difficile (C. difficile) and aerobic Gram-positive bacteria but little activity against Gram-negative bacteria, including anaerobes. CRS3123 has the potential for the research of C. difficile infections.
    CRS3123
  • HY-18667
    LTV-1 347379-29-7 98.0%
    LTV-1 is a potent lymphoid tyrosine phosphatase (LYP) inhibitor in T cells with an IC50 of 508 nM. LTV-1 has the potential for autoimmunity treatment.
    LTV-1
  • HY-107352
    Fosfenopril 95399-71-6 99.85%
    Fosfenopril (Fosinoprilat) is a potent angiotensin converting enzyme (ACE) inhibitor. Fosfenopril alleviates lipopolysaccharide (LPS)-induced inflammation by inhibiting TLR4/NF-κB signaling in monocytes.
    Fosfenopril
  • HY-109154
    Obafistat 2160582-57-8 99.92%
    Obafistat is a potent aldo-keto reductase AKR1C3 inhibitor with an IC50 of 1.2 nM for human AKR1C3 (patent WO2017202817A1, example 4).
    Obafistat
  • HY-124295
    Imofinostat 1338320-94-7 99.40%
    Imofinostat (ABT-301; MPT0E028) is an orally active and selective HDAC inhibitor with IC50s of 53.0 nM, 106.2 nM, 29.5 nM for HDAC1, HDAC2 and HDAC6, respectively. Imofinostat has a weak inhibitory effect on HDAC8 (IC50 of 2.5 ​​μM), but no inhibitory effect on HDAC4 (IC50>10 μM). Imofinostat reduces the viability of B-cell lymphomas by inducing apoptosis and possesses potent direct Akt targeting ability and reduces Akt phosphorylation in B-cell lymphoma. Imofinostat has a broad-spectrum antitumor activity, including colorectal cancer, B-cell lymphoma, non-small cell lung carcinoma (NSCLC), and pancreatic cancer, while also showing therapeutic potential in non-tumor diseases like emphysema and pulmonary fibrosis.
    Imofinostat
  • HY-131335
    p38α inhibitor 2 1095003-80-7 98.33%
    p38α inhibitor 2 is a highly potent and selective p38α MAPK inhibitor, with a pIC50 of 9.6. p38α inhibitor 2 inhibits the hERG ion channel (IC50=27 μM) and shows a promising selectivity profile when tested in a panel of 51 other protein kinases (<30% inhibition at 10 μM concentration) and a panel of 141 other biological targets.
    p38α inhibitor 2
Cat. No. Product Name / Synonyms Application Reactivity